Tafamidis Meglumine Patent Expiration
Tafamidis Meglumine is Used for treating the cardiomyopathy associated with transthyretin-mediated amyloidosis. It was first introduced by Foldrx Pharmaceuticals Llc A Wholly Owned Sub Of Pfizer Inc
Tafamidis Meglumine Patents
Given below is the list of patents protecting Tafamidis Meglumine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vyndaqel | US7214695 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | Dec 19, 2026 | Foldrx Pharms |
| Vyndaqel | US7214696 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | Dec 19, 2026 | Foldrx Pharms |
| Vyndaqel | US8168663 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof |
Dec 19, 2023
(Expired) | Foldrx Pharms |
| Vyndaqel | US8653119 | Methods for treating transthyretin amyloid diseases |
Dec 19, 2023
(Expired) | Foldrx Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Tafamidis Meglumine's patents.
Latest Legal Activities on Tafamidis Meglumine's Patents
Given below is the list recent legal activities going on the following patents of Tafamidis Meglumine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Interim Patent Term Extension Granted | 15 Aug, 2025 | US7214695 |
| Interim Patent Term Extension Granted | 15 Aug, 2025 | US7214696 |
| Interim Patent Term Extension Request Under 35 USC 156(e)(2) | 13 Aug, 2025 | US7214695 |
| Interim Patent Term Extension Request Under 35 USC 156(e)(2) | 13 Aug, 2025 | US7214696 |
| transaction for FDA Determination of Regulatory Review Period | 30 Oct, 2024 | US7214695 |
| transaction for FDA Determination of Regulatory Review Period | 21 Oct, 2024 | US7214696 |
| transaction for FDA Determination of Regulatory Review Period | 21 Oct, 2024 | US7214695 |
| Interim Patent Term Extension Granted | 17 Sep, 2024 | US7214695 |
| Interim Patent Term Extension Granted | 17 Sep, 2024 | US7214696 |
| Second letter to regulating agency to determine regulatory review period | 29 Apr, 2024 | US7214696 |
Tafamidis Meglumine's Family Patents
